Indivior PLC (NASDAQ:INDV) Shares Purchased by XTX Topco Ltd

Key Points

• XTX Topco Ltd significantly increased its stake in Indivior PLC by 123.9%, bringing its total ownership to 50,437 shares valued at approximately $481,000.
• Several institutional investors, including Deerfield Management Company L.P. and Marshall Wace LLP, also boosted their holdings in Indivior, reflecting strong interest from hedge funds.
• Analysts have a consensus rating of "Buy" on Indivior stock, with targets ranging from $19.60 to $27.00, indicating positive sentiment towards the company’s future performance.

XTX Topco Ltd increased its position in Indivior PLC (NASDAQ:INDV - Free Report) by 123.9% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 50,437 shares of the company's stock after purchasing an additional 27,906 shares during the period. XTX Topco Ltd's holdings in Indivior were worth $481,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in INDV. Legal & General Group Plc lifted its holdings in shares of Indivior by 1.4% in the 4th quarter. Legal & General Group Plc now owns 715,920 shares of the company's stock valued at $9,181,000 after purchasing an additional 9,978 shares during the last quarter. Rathbones Group PLC lifted its holdings in shares of Indivior by 11.6% in the 4th quarter. Rathbones Group PLC now owns 14,284 shares of the company's stock valued at $183,000 after purchasing an additional 1,483 shares during the last quarter. Marshall Wace LLP raised its stake in Indivior by 659.7% during the 4th quarter. Marshall Wace LLP now owns 506,782 shares of the company's stock valued at $6,299,000 after acquiring an additional 440,072 shares during the last quarter. Claret Asset Management Corp purchased a new stake in Indivior during the 4th quarter valued at approximately $9,304,000. Finally, Stifel Financial Corp raised its stake in Indivior by 24.0% during the 4th quarter. Stifel Financial Corp now owns 12,675 shares of the company's stock valued at $158,000 after acquiring an additional 2,450 shares during the last quarter. 60.33% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts have commented on INDV shares. Craig Hallum upped their price objective on Indivior from $15.00 to $22.00 and gave the company a "buy" rating in a research note on Monday, June 30th. Jefferies Financial Group started coverage on Indivior in a research note on Tuesday, July 22nd. They set a "buy" rating and a $20.00 price objective for the company. Wall Street Zen raised Indivior from a "buy" rating to a "strong-buy" rating in a research note on Saturday, June 21st. Finally, HC Wainwright started coverage on Indivior in a research note on Wednesday, August 6th. They set a "buy" rating and a $27.00 price objective for the company. Five equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, Indivior has an average rating of "Buy" and an average price target of $19.60.

Indivior Stock Performance

NASDAQ INDV traded up $0.29 on Tuesday, hitting $22.58. 820,851 shares of the company's stock were exchanged, compared to its average volume of 1,787,063. The firm's 50-day moving average price is $16.02 and its two-hundred day moving average price is $12.32. Indivior PLC has a fifty-two week low of $7.33 and a fifty-two week high of $22.86.

Indivior (NASDAQ:INDV - Get Free Report) last released its earnings results on Thursday, July 31st. The company reported $0.51 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.26 by $0.25. Indivior had a negative return on equity of 86.28% and a net margin of 6.65%. The company had revenue of $302.00 million for the quarter, compared to analysts' expectations of $239.43 million. Research analysts expect that Indivior PLC will post 1.22 EPS for the current year.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.